Squarepoint
TEVA icon

Squarepoint’s Teva Pharmaceuticals TEVA Stock Holding History

Squarepoint’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
57,807
-109,773
-66% -$3.66M ﹤0.01% 2356
2026
Q1 		$5.05M Buy
167,580
+26,714
+19% +$859K 0.01% 1497
2025
Q4 		$4.4M Buy
140,866
+13,329
+10% +$328K ﹤0.01% 1541
2025
Q3 		$2.58M Buy
127,537
+38,477
+43% +$676K ﹤0.01% 1897
2025
Q2 		$1.49M Sell
89,060
-576,737
-87% -$9.31M ﹤0.01% 2317
2025
Q1 		$10.2M Buy
665,797
+353,168
+113% +$6.31M 0.01% 1016
2024
Q4 		$6.89M Buy
312,629
+297,031
+1,904% +$5.4M 0.01% 1392
2024
Q3 		$281K Buy
+15,598
New +$273K ﹤0.01% 3492
2023
Q3 		– Sell
-313,436
Closed -$2.36M – 4245
2023
Q2 		$2.36M Buy
313,436
+287,547
+1,111% +$2.33M 0.01% 1551
2023
Q1 		$229K Buy
+25,889
New +$256K ﹤0.01% 2723
2022
Q3 		– Sell
-46,262
Closed -$348K – 3435
2022
Q2 		$348K Sell
46,262
-48,025
-51% -$418K ﹤0.01% 2209
2022
Q1 		$885K Sell
94,287
-394
-0.4% -$3.29K ﹤0.01% 1664
2021
Q4 		$758K Sell
94,681
-262,867
-74% -$2.37M ﹤0.01% 1872
2021
Q3 		$3.48M Buy
357,548
+255,708
+251% +$2.39M 0.01% 939
2021
Q2 		$1.01M Sell
101,840
-558,269
-85% -$5.91M ﹤0.01% 1621
2021
Q1 		$7.62M Buy
660,109
+554,855
+527% +$6.36M 0.04% 459
2020
Q4 		$1.02M Buy
+105,254
New +$1.01M 0.01% 1319
2020
Q3 		– Sell
-122,418
Closed -$1.51M – 2834
2020
Q2 		$1.51M Buy
+122,418
New +$1.38M 0.02% 742
2020
Q1 		– Sell
-80,508
Closed -$789K – 2497
2019
Q4 		$789K Sell
80,508
-17,965
-18% -$160K ﹤0.01% 1487
2019
Q3 		$677K Sell
98,473
-97,508
-50% -$747K 0.01% 1457
2019
Q2 		$1.81M Buy
195,981
+65,458
+50% +$789K 0.02% 903
2019
Q1 		$2.05M Buy
130,523
+91,205
+232% +$1.61M 0.02% 764
2018
Q4 		$606K Sell
39,318
-34,398
-47% -$705K 0.01% 1155
2018
Q3 		$1.59M Buy
73,716
+50,713
+220% +$1.18M 0.02% 806
2018
Q2 		$559K Buy
+23,003
New +$469K 0.01% 1143
2017
Q4 		– Sell
-73,361
Closed -$1.29M – 2337
2017
Q3 		$1.29M Buy
+73,361
New +$1.65M 0.02% 643

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Squarepoint's TEVA Position: Q2 2026 in Review

Squarepoint reduced its Teva Pharmaceuticals (TEVA) stake by 66% in Q2 2026, selling an estimated $3.66M and leaving 57,807 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Squarepoint first reported a position in TEVA in Q3 2017 and has held it in 26 quarters since. The position peaked at $10.2M in Q1 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Squarepoint held 57,807 shares of Teva Pharmaceuticals worth $1.96M as of Q2 2026.
  • Squarepoint sold 109,773 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.66M.
  • Teva Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2356 holding.
  • Squarepoint first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 26 quarters since.
  • Squarepoint's Teva Pharmaceuticals position peaked at $10.2M in Q1 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.